--- title: "Cbdmd Inc Earnings Call: Growth Amid Margin Pressure" type: "News" locale: "en" url: "https://longbridge.com/en/news/286627322.md" description: "Cbdmd Inc reported Q2 earnings with net sales of $5.6 million, a 19% year-over-year increase. Despite revenue growth, the company faces margin pressure and cash burn due to a shift towards wholesale sales and integration costs from the Bluebird Botanicals acquisition. Management remains optimistic about future growth, particularly with new Medicare-linked opportunities, while targeting EBITDA breakeven. The net loss narrowed to $876,000, and cash reserves stand at $2.6 million, indicating a focus on operational efficiency and strategic investments." datetime: "2026-05-16T00:18:28.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/286627322.md) - [en](https://longbridge.com/en/news/286627322.md) - [zh-HK](https://longbridge.com/zh-HK/news/286627322.md) --- # Cbdmd Inc Earnings Call: Growth Amid Margin Pressure Cbdmd INc ((YCBD)) has held its Q2 earnings call. Read on for the main highlights of the call. ### Claim 55% Off TipRanks - Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions - Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks Cbdmd Inc’s latest earnings call struck a cautiously optimistic tone, blending clear operational gains with ongoing financial and regulatory pressures. Management highlighted accelerating revenue growth, early wins from the Bluebird Botanicals deal, and a strategic push into a new Medicare-linked medical channel, while acknowledging margin pressure, cash burn, and state-level rule changes as key near-term headwinds. ## Revenue Growth Reaccelerates on Sequential and Year-Over-Year Basis Cbdmd reported Q2 net sales of $5.6 million, up 19% from a year ago and 12% sequentially from Q1 FY2026, signaling renewed topline momentum. This return to growth is central to management’s narrative that the business is stabilizing and building a higher base from which to pursue both retail and medical opportunities. ## Core Business Strength Excluding Bluebird Acquisition Effects Stripping out the impact of the Bluebird Botanicals acquisition, core revenue increased about $0.5 million year-over-year and roughly $0.3 million sequentially. The company said this was its highest quarterly core revenue since December 2023, underscoring that the underlying business is expanding even before fully realizing synergies from the new brand. ## Channel Mix Shifts as Wholesale Surges Alongside DTC Direct-to-consumer sales remained the anchor at around 67% of revenue, but wholesale jumped to 33% from 23% in the prior-year quarter. Wholesale revenue surged 65% year-over-year, reflecting stronger retail partnerships though also contributing to margin pressure as the mix tilts toward lower-priced bulk sales. ## Bluebird Botanicals Acquisition Tracks Toward Q3 Accretion The mid-January purchase of Bluebird weighed on Q2 results through transition and integration costs that hit earnings without a full quarter of revenue. Management noted Bluebird began contributing positively in March and expressed confidence that the deal should shift from drag to accretive for both revenue and earnings in Q3. ## Regulatory Tailwinds from CMS BEI and Federal Developments The April 1 activation of the CMS substance access beneficiary engagement incentive created a new federally supported pathway for hemp-derived CBD in Medicare. Cbdmd has accelerated investment in a dedicated clinical and healthcare channel around this program, expecting provider adoption and revenue to build gradually over the next 12 to 18 months. ## Improved Per-Share Loss and Flexible Capital Positioning Net loss attributable to common shareholders narrowed to about $876,000, or $0.08 per share, versus roughly $1.4 million, or $1.90 per share, a year earlier, helped by eliminating or converting the Series A preferred dividend. The company ended the quarter with approximately $2.6 million in cash and pointed to available equity facilities and an ELOC to support operations and strategic investments. ## Management Targets Path Toward EBITDA Breakeven Adjusted non-GAAP EBITDA loss came in at $220,000, with management emphasizing that EBITDA and working capital efficiency should improve as integration costs ease and revenue scales. They estimate quarterly breakeven revenue is well below $7 million, suggesting that modest incremental growth could bring the business close to operating cash neutrality. ## Gross Margin Compression from Mix Shift and State Costs Gross margin slipped to 58% from 62% in the year-ago period, a four-point decline driven largely by a higher wholesale mix and incremental state-level compliance costs. New requirements such as repacking and expanded testing have added friction and cost to the supply chain even as the company leans into higher-volume wholesale relationships. ## Operating Loss Widens on One-Time and Growth Investments Loss from operations widened to roughly $801,000 versus about $486,000 a year earlier, an increase of around 65% amid integration and growth spending. Excluding a one-time noncash stock vesting charge, operating loss would have been approximately $405,000, a level management argues is more representative of underlying performance. ## Adjusted EBITDA Reflects Payroll, Deal Costs, and CMS Spend The $220,000 adjusted non-GAAP EBITDA loss was driven by payroll, acquisition-related expenses, and stepped-up strategic investments tied to the CMS BEI program. Management framed these outlays as front-loaded costs aimed at capturing emerging medical-channel demand, even though they weigh on near-term profitability metrics. ## Working Capital Build Fuels Cash Burn and Liquidity Pressure Operating cash use was about $723,000, with a roughly $435,000 increase in accounts receivable from growth in wholesale and related payment terms and about $240,000 in additional inventory, excluding acquired stock. While these working capital builds support higher sales, they also tighten near-term liquidity despite the company’s credit lines and equity tools. ## Acquisition Drag and Integration Costs Temporarily Depress Earnings Management acknowledged that Bluebird’s Q2 impact was disproportionately negative because cbdmd absorbed transition and integration expenses without a full quarter of revenue. They argue that as integration completes and combined operations scale, the acquisition should become a net positive to margins and earnings beginning in Q3. ## State Regulatory Volatility Raises Structural Costs and Risks Ongoing state-level regulatory shifts remain a structural headwind, forcing repacking and retesting spending, SKU limitations, and occasional market disruptions. Management cited the example of a law change in Alabama that curtailed hemp-derived product sales, illustrating the compliance complexity and uncertainty embedded in cbdmd’s operating environment. ## Long-Dated Medical Channel Opportunity Carries Execution Risk The CMS BEI-linked medical channel is positioned as a major strategic pillar but with a long lead time and multiple execution hurdles. Cbdmd expects a 12- to 18-month adoption curve as it builds clinical evidence, educates providers, and proves economic value before this pathway can materially move the revenue needle. ## Guidance and Outlook Emphasize Margin Repair and Cash Discipline Looking ahead, management expects Bluebird to turn accretive in Q3 while core momentum continues, building on Q2’s 19% year-over-year and 12% sequential sales growth and stronger wholesale mix. They aim to lift the 58% gross margin, narrow operating and EBITDA losses, reduce cash burn from the $723,000 Q2 level, and advance the CMS BEI medical channel and regulatory contingency planning through 2026 while preserving balance-sheet flexibility. Cbdmd’s earnings call painted a picture of a company leaning into growth and regulatory-driven opportunity despite near-term profitability and liquidity pressures. For investors, the key questions will be whether management can convert wholesale and Bluebird momentum into stronger margins, manage cash prudently, and execute on the long-cycle Medicare channel without overextending the balance sheet. ### Related Stocks - [YCBD.US](https://longbridge.com/en/quote/YCBD.US.md) - [YCBD-A.US](https://longbridge.com/en/quote/YCBD-A.US.md) ## Related News & Research - [Herbal Dispatch Completes Company Record 500kg Medical Cannabis Export Shipment to Europe | LUFFF Stock News](https://longbridge.com/en/news/286883156.md) - [ANCOM designates Digi Romania as significant market power, mandates wholesale fixed access](https://longbridge.com/en/news/287021651.md) - [How Investors May Respond To American Healthcare REIT (AHR) Cutting 2026 Profit Outlook After Q1 Results](https://longbridge.com/en/news/286866277.md) - [Akari Therapeutics to Present at A.G.P.’s Annual Healthcare Company Showcase | AKTX Stock News](https://longbridge.com/en/news/286776452.md) - [Trump faces record-low approval on inflation as retirees struggle](https://longbridge.com/en/news/286834439.md)